Perhaps reflecting concerns about the size and growth of the market for HPV shots and GSK's late entry, investors are not enthusiastic about the prestigious publication of the company's robust new test results. As I write this, GSK shares are the biggest percentage loser in big pharma.   Read More

Today the Food and Drug Administration announced that Pfizer's Chantix and GlaxoSmithKline's Zyban will carry new warnings about mental side effects. Not just any old warnings, but so-called "Black Box" warnings. Or, at least, that's what we in the news media used to call them. Until the FDA called us out today.    Read More

Shares of Sanofi-Aventis are getting a little investor injection on the back of the emergency release of the Lantus diabetic insulin studies late last Friday.    Read More

Shares of the French drugmaker are getting pummeled over at least three analyst reports identifying a leak about a study or studies that could go public soon. Their research suggests the data is related to a suspected or "theoretical" higher cancer risk associated with SNY's Lantus.    Read More

The bears seized control of trading on Tuesday sending the Dow sharply lower as mixed economic data and disappointing sales from Best Buy sparked worries about a recovery.   Read More

As healthcare lands squarely in Washington’s sights, how should you play the sector?   Read More

To almost no one's surprise, for the first time in 41 years, the World Health Organization has declared a full-blown swine flu pandemic. But the declaration is tied more to the geographic spread of the virus than it is to its virulence.    Read More

It’s bathing suit time. Considering almost no one likes how they look nearly naked, what’s the trade?   Read More

For people struggling with diabetes, the bathroom scale can be the enemy. But new developments may change that and more!   Read More

Cramer makes the call on viewers' favorite stocks.   Read More